Spyre Therapeutics, Inc. SYRE Proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs
Proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept syre:ProceedsFromIssuanceOfCommonStockAtTheMarketOfferingsNet.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs?
- Spyre Therapeutics, Inc. (SYRE) reported proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs of $9.75M in Q1 2026.
- What does proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs mean?
- This represents cash raised through the sale of common stock via an At-The-Market (ATM) offering program, where shares are sold incrementally into the public market. It is a flexible financing tool used to raise capital without the market impact of a large, singular follow-on offering.